Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/7626
Full metadata record
DC FieldValue
dc.contributor.authorGiusta, Caroline Junqueira
dc.contributor.authorGuerrero, Ana Tereza
dc.contributor.authorGalvão Filho, Bruno
dc.contributor.authorAndrade, Warrison Athanásio Coelho de
dc.contributor.authorSalgado, Ana Paula Carneiro
dc.contributor.authorCunha, Thiago Mattar
dc.contributor.authorRopert, Catherine
dc.contributor.authorCampos, Marco Antônio da Silva
dc.contributor.authorPenido, Marcus Luiz de Oliveira
dc.contributor.authorPreviato, Lúcia Mendonça
dc.contributor.authorPreviato, Jose Oswaldo
dc.contributor.authorRitter, Gerd
dc.contributor.authorCunha, Fernando Queiroz
dc.contributor.authorGazzinelli, Ricardo Tostes
dc.date.accessioned2014-05-14T16:09:13Z
dc.date.available2014-05-14T16:09:13Z
dc.date.issued2012
dc.identifier.citationJUNQUEIRA, Caroline et al. Trypanosoma cruzi adjuvants potentiate T Cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. Plos One. 2012, vol.7, pp. e36245
dc.identifier.issn1932-6203
dc.identifier.urihttps://www.arca.fiocruz.br/handle/icict/7626
dc.language.isoeng
dc.publisherPublic Library of Science
dc.rightsopen access
dc.titleTrypanosoma cruzi adjuvants potentiate T Cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine
dc.typeArticle
dc.identifier.doi10.1371/journal.pone.0036245
dc.description.abstractenImmunological adjuvants that induce T cell-mediate immunity (TCMI) with the least side effects are needed for the development of human vaccines. Glycoinositolphospholipids (GIPL) and CpGs oligodeoxynucleotides (CpG ODNs) derived from the protozoa parasite Trypanosoma cruzi induce potent pro-inflammatory reaction through activation of Toll-Like Receptor (TLR) 4 and TLR9, respectively. Here, using mouse models, we tested the T. cruzi derived TLR agonists as immunological adjuvants in an antitumor vaccine. For comparison, we used well-established TLR agonists, such as the bacterial derived monophosphoryl lipid A (MPL), lipopeptide (Pam3Cys), and CpG ODN. All tested TLR agonists were comparable to induce antibody responses, whereas significant differences were noticed in their ability to elicit CD4(+) T and CD8(+) T cell responses. In particular, both GIPLs (GTH, and GY) and CpG ODNs (B344, B297 and B128) derived from T. cruzi elicited interferon-gamma (IFN-gamma) production by CD4(+) T cells. On the other hand, the parasite derived CpG ODNs, but not GIPLs, elicited a potent IFN-gamma response by CD8(+) T lymphocytes. The side effects were also evaluated by local pain (hypernociception). The intensity of hypernociception induced by vaccination was alleviated by administration of an analgesic drug without affecting protective immunity. Finally, the level of protective immunity against the NY-ESO-1 expressing melanoma was associated with the magnitude of both CD4+ T and CD8+ T cell responses elicited by a specific immunological adjuvant.
dc.creator.affilliationFundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil/Universidade Federal de Minas Gerais. Departamento de Bioquımica e Imunologia. Belo Horizonte, MG, Brazil
dc.creator.affilliationFundaçao Oswaldo Cruz. Instituto Cerrado Pantanal. Campo Grande, MT, Brazil
dc.creator.affilliationFundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil/Universidade Federal de Minas Gerais. Departamento de Bioquımica e Imunologia. Belo Horizonte, MG, Brazil,
dc.creator.affilliationFundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil/Universidade Federal de Minas Gerais. Departamento de Bioquımica e Imunologia. Belo Horizonte, MG, Brazil/University of Massachusetts. Medical School. Division of Infectious Diseases and Immunology. Worcester, MA, United States of America
dc.creator.affilliationFundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil
dc.creator.affilliationUniversidade de Sao Paulo. Faculdade de Medicina de Ribeirao Preto. Departamento de Farmacologia. Ribeirao Preto, SP, Brazil
dc.creator.affilliationFundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil
dc.creator.affilliationFundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil
dc.creator.affilliationUniversidade Federal de Minas Gerais. Departamento de Bioquımica e Imunologia. Belo Horizonte, MG, Brazil
dc.creator.affilliationInstituto de Biofısica Carlos Chagas Filho. Centro de Ciencias da Saude. Universidade Federal do Rio de Janeiro. Rio de Janeiro, Brazil
dc.creator.affilliationInstituto de Biofısica Carlos Chagas Filho. Centro de Ciencias da Saude. Universidade Federal do Rio de Janeiro. Rio de Janeiro, Brazil
dc.creator.affilliationNew York Branch at Memorial Sloan–Kettering Cancer Center.Ludwig Institute for Cancer Research. New York, New York, United States of America
dc.creator.affilliationUniversidade de Sao Paulo. Faculdade de Medicina de Ribeirao Preto. Departamento de Farmacologia. Ribeirao Preto, SP, Brazil
dc.creator.affilliationFundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil/Universidade Federal de Minas Gerais. Departamento de Bioquımica e Imunologia. Belo Horizonte, MG, Brazil/University of Massachusetts. Medical School. Division of Infectious Diseases and Immunology. Worcester, MA, United States of America
dc.subject.enTrypanosoma cruzi
dc.subject.enimmunology
Appears in Collections:MG - IRR - Artigos de Periódicos



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.